⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308536 | 0.82 | — | — | |
| SCHEMBL3864690 | 0.79 | TDP1 (0.50) | — | |
| SCHEMBL3072338 | 0.79 | TDP1 (0.32) | — | |
| SCHEMBL15531820 | 0.78 | — | — | |
| SCHEMBL17599666 | 0.78 | CA12 (0.33) | — | |
| SCHEMBL10403166 | 0.78 | — | — | |
| SCHEMBL12360851 | 0.77 | ALDH1A1 (0.34) | — | |
| SCHEMBL6549717 | 0.77 | MAPT (0.39) | — | |
| SCHEMBL17036860 | 0.77 | — | — | |
| SCHEMBL16940261 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-05-16 | — | — | US | claimed |
| EP-3442983-A1 | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE | H. Hoffnabb-La Roche Ag (CH) | 2019-02-20 | — | — | EP | claimed |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN-LA ROCHE INC. | 2017-11-16 | — | — | US | claimed |
| WO-2017178656-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-10-19 | — | — | WO | claimed |
| EP-3204397-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | claimed |
| WO-2016055601-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | claimed |
| US-11248019-B2 | Trityl-mono-GalNAc compounds and their use | HOFFMANN-LA ROCHE INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210017214-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN LA ROCHE (US) | 2021-01-21 | — | — | US | disclosed |
| CN-106795200-B | Galnac phosphoramidites, nucleic acid conjugates thereof, and uses thereof | 豪夫迈·罗氏有限公司 | 2020-06-19 | — | — | CN | disclosed |
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-05-16 | — | — | US | disclosed |
| EP-3442983-A1 | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE | H. Hoffnabb-La Roche Ag (CH) | 2019-02-20 | — | — | EP | disclosed |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN-LA ROCHE INC. | 2017-11-16 | — | — | US | disclosed |
| WO-2017178656-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-10-19 | — | — | WO | disclosed |
| EP-3204397-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055601-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| US-6242589-B1 | RESISTANT TO NUCLEASE DEGRADATION AND GOOD HYBRIDIZATION CHARACTERISTICS; ANTISENSE AGENTS FOR DIAGNOSIS AND THERAPY | ISIS PHARMACEUTICALS, INC. | 2001-06-05 | — | — | US | disclosed |